Skip to content

Clinical study of the intervention of Yiqi Huoxue therapy in sepsis-related cardiac dysfunction

Clinical study of the intervention of Yiqi Huoxue therapy in sepsis-related cardiac dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109244
Enrollment
Unknown
Registered
2025-09-16
Start date
2023-07-26
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-related cardiac dysfunction

Interventions

Control group:(0.9% NS 100ML) Sodium Chloride Injection

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.It also meets the diagnostic criteria for sepsis and heart failure. 2.Traditional Chinese medicine distinguishes as qi deficiency and blood stasis. 3.Age 18~80 years old. 4.Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Those under the age of 18 or over 80, or pregnant or lactating women. 2.Patients with irreversible underlying diseases or expected death within 48 hours, such as advanced malignant tumors, extremely severe head injury, etc. 3.Allergic constitution, or known to be allergic to the ingredients of this medicine. 4.Patients who have given up rescue and cannot undergo conventional Western medicine and basic vital signs support therapy. 5.Those who do not meet the inclusion criteria, do not use and treat as prescribed, or have incomplete data that affect the efficacy or safety judgment.

Design outcomes

Primary

MeasureTime frame
Left Ventricular Ejection Fractions;Cardiac Index;Fractional shortening;Left Ventricular End-diastolic Dimension;E/A;E/e';Lactate;Central Venous Oxygen Saturation;Pv-aCO2;Urine output;

Secondary

MeasureTime frame
Brain Natriuretic Peptide;Cardiac Troponin I;Endocan;Vascular Endothelial Growth Factor;Endothelin-1;Soluble Thrombomodulin;Tumornecrosisfactor-a;Interleukin-1ß;Complement C5a;Sequential organ failure;Acute physiology and chronic health evaluation II;Time of mechanical ventilation;Length of ICU stay;ICU case fatality rate;28-day case fatality rate;

Countries

China

Contacts

Public ContactGuo Tao

Jiangsu Provincial Hospital of Traditional Chinese Medicine

saharaicu@126.com+86 138 1390 5939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026